Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen, Rosanne G
Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement. [electronic resource] - Acta dermato-venereologica 2009 - 518-20 p. digital
Publication Type: Clinical Trial; Letter
1651-2057
10.2340/00015555-0675 doi
Adult
Antibodies, Monoclonal--therapeutic use
Biopsy
Dermatologic Agents--therapeutic use
Dipeptidyl Peptidase 4--metabolism
Female
Humans
Infliximab
Keratinocytes--drug effects
Male
Middle Aged
Psoriasis--drug therapy
Severity of Illness Index
T-Lymphocytes--drug effects
Time Factors
Treatment Outcome
Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement. [electronic resource] - Acta dermato-venereologica 2009 - 518-20 p. digital
Publication Type: Clinical Trial; Letter
1651-2057
10.2340/00015555-0675 doi
Adult
Antibodies, Monoclonal--therapeutic use
Biopsy
Dermatologic Agents--therapeutic use
Dipeptidyl Peptidase 4--metabolism
Female
Humans
Infliximab
Keratinocytes--drug effects
Male
Middle Aged
Psoriasis--drug therapy
Severity of Illness Index
T-Lymphocytes--drug effects
Time Factors
Treatment Outcome